Logo Geneseeq
  • Products
    • Solid Tumors
      • Pan-Cancer
      • Cancer Type-Specific
      • Minimal Residual Disease
    • Hematologic Malignancies
      • Pan-Cancer
      • Cancer Type-Specific
    • Cancer Early Detection
    • Hereditary Cancers
  • Services
    • Central Lab Testing
    • Local Testing Solutions
      • IVD Kit Solutions
      • RUO Kit Solutions
    • Research Services
      • DNA Sequencing
      • RNA Sequencing
  • Technology
    • Our Technology
    • Publications
  • Partnerships
  • About Us
    • What is Precision Oncology?
    • Our Company
    • Our Team
    • Certificates & Accreditation
  • News
    • Newsroom
    • Geneseeq Blogs
  • Join Us
  • Contact Us
  • Search

October 17, 2023

Geneseeq to present four studies at ESMO 2023

by Geneseeq

August 31, 2021

Geneseeq Study Evaluates ctDNA MRD to Predict Response to Therapy and Assess Prognosis in Locally Advanced Rectal Cancer

by GENESEEQ

May 18, 2021

Geneseeq study shows ctDNA evaluation in early postoperative phase predicts risk of recurrence in colorectal cancer

by GENESEEQ

Logo Geneseeq

1-647-714-5020
1-800-362-0325
info@geneseeq.ca

Quick Links
  • Services
  • Technology
  • News
  • About Us
Connect
  • Partnerships
  • Join us
  • Contact us
Privacy
  • Privacy Policy
  • Terms of Use
Headquarters

Main Office:
Suite 1802
393 University Avenue
Toronto, Ontario, M5G 1E6
Canada

© 2026 Geneseeq Technology Inc. | A Precision Oncology Company. All rights reserved

Privacy Preference Center

Privacy Preferences

    FDA Cleared IVD kit